Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SERPINA6 | P08185 | 4/20 | 0.67 |
| ▸ | SHBG | P04278 | 4/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | THRB | P10828 | 1/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.52 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.52 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.51 |
| ▸ | AR | P10275 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | SNCA | P37840 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31304050 | 1.00 | SERPINA6 (0.67) | SERPINA6SHBGSLC22A1ALDH1A1THRB | |
| SCHEMBL3453459 | 1.00 | SERPINA6 (0.67) | SERPINA6SHBGSLC22A1ALDH1A1THRB | |
| SCHEMBL13372794 | 0.82 | SERPINA6 (0.48) | SERPINA6SHBGSLC22A1ALDH1A1THRB | |
| Nandrolone SCHEMBL17831191 | 0.80 | ALDH1A1 (1.00) | SERPINA6SHBGSLC22A1ALDH1A1THRB | |
| Nandrolone SCHEMBL22739132 | 0.80 | ALDH1A1 (1.00) | SERPINA6SHBGSLC22A1ALDH1A1THRB | |
| Nandrolone SCHEMBL11977556 | 0.80 | ALDH1A1 (1.00) | SERPINA6SHBGSLC22A1ALDH1A1THRB | |
| Nandrolone SCHEMBL5017882 | 0.80 | ALDH1A1 (1.00) | SERPINA6SHBGSLC22A1ALDH1A1THRB | |
| Nandrolone SCHEMBL12101449 | 0.80 | ALDH1A1 (1.00) | SERPINA6SHBGSLC22A1ALDH1A1THRB | |
| Nandrolone SCHEMBL11736454 | 0.80 | ALDH1A1 (1.00) | SERPINA6SHBGSLC22A1ALDH1A1THRB | |
| Nandrolone SCHEMBL11872554 | 0.80 | ALDH1A1 (1.00) | SERPINA6SHBGSLC22A1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023244059-A1 | METHODS OF TREATING CANCER USING DUAL ANDROGEN RECEPTOR AND PDE5 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-12-21 | — | — | WO | disclosed |
| EP-4259634-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-10-17 | — | — | US | disclosed |
| US-20220194948-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | ILDONG PHARACEUTICAL CO., LTD. (KR) | 2022-06-23 | — | — | US | disclosed |
| WO-2022123310-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-06-16 | — | — | WO | disclosed |
| US-10948484-B2 | Sample depletion and enrichment to improve the quality of diagnostic test results | VERAVAS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190137484-A9 | Sample depletion and enrichment to improve the quality of diagnostic test results | VERAVAS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20180292394-A1 | Sample depletion and enrichment to improve the quality of diagnostic test results | SOLDO JOSHUA CAINE (US) | 2018-10-11 | — | — | US | disclosed |
| EP-1578719-A4 | STEREOISOMERS OF P-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF | COLLEGIUM PHARMACEUTICAL INC (US) | 2006-07-05 | — | — | EP | disclosed |
| US-7038085-B2 | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1578719-A2 | STEREOISOMERS OF P-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF | Collegium Pharmaceutical, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20040142904-A1 | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof | COLLEGIUM PHARMACEUTICAL INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004039320-A2 | STEREOISOMERS OF p-HYDROXY-MILNACIPRAN, AND METHODS OF USE THEREOF | COLLEGIUM PHARMACEUTICAL, INC. (US) | 2004-05-13 | — | — | WO | disclosed |
| WO-2001021009-A2 | STANDARDIZED FUNCTIONAL FOOD PRODUCTS | CURRIER STEPHEN J (US) | 2001-03-29 | — | — | WO | disclosed |
| US-6074625-A | USING COMPLEX OF BORON ISOTOPE | NEUTRON THERAPIES INC. (US) | 2000-06-13 | — | — | US | disclosed |
| EP-0729363-A4 | BORON-CONTAINING HORMONE ANALOGS AND METHODS OF THEIR USE IN IMAGING OR KILLING CELLS HAVING HORMONE RECEPTORS | IONIX CORP (US) | 1998-08-19 | — | — | EP | disclosed |
| EP-0729363-A1 | BORON-CONTAINING HORMONE ANALOGS AND METHODS OF THEIR USE IN IMAGING OR KILLING CELLS HAVING HORMONE RECEPTORS | IONIX CORPORATION (US) | 1996-09-04 | — | — | EP | disclosed |
| WO-1996000090-A1 | BORON-CONTAINING HORMONE ANALOGS AND METHODS OF THEIR USE IN IMAGING OR KILLING CELLS HAVING HORMONE RECEPTORS | IONIX CORPORATION (US) | 1996-01-04 | — | — | WO | disclosed |
| US-5096694-A | Chloromethyl- and radioactive iodine substituted hydroxygonane derivatives | IRE-CELLTARG S.A. (BE) | 1992-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142904-A1 | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof | SLC6A2, SLC6A4, OPRL1 | SERPINA6 2265/4885SHBG 1689/4885SLC22A1 332/4885 |
| US-11787812-B2 | Substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1 -f][1,2,4]triazines as androgen receptor and phosphodiesterase dual inhibitors | PDE5A, AR, PDE3A | SERPINA6 2676/4885SHBG 26/4885SLC22A1 4489/4885 |
| US-20220194948-A1 | NOVEL COMPOUNDS AS ANDROGEN RECEPTOR AND PHOSPHODIESTERASE DUAL INHIBITOR | AR, PDE5A, PDE1A | SERPINA6 2029/4885SHBG 18/4885SLC22A1 4659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.